Methylene blue vs NMN (Niagen): how the two compare

Last updated 2026-07-27

What is the actual difference between methylene blue and NMN/Niagen?

Methylene blue (methylthioninium chloride) is a synthetic phenothiazine dye that has been an FDA-approved drug since 1891 for treating methemoglobinemia, a condition where blood can't carry oxygen properly ^[1]. It also has approved and off-label uses in surgery (as a tissue marker) and is being studied for ifosfamide-induced encephalopathy. The FDA label for methylene blue injection is explicit about its pharmacology: it works as a monoamine oxidase inhibitor (MAOI) at the doses used clinically ^[1]. NMN (nicotinamide mononucleotide) is not a drug at all. It's a naturally occurring molecule your body makes as a precursor to NAD+, the coenzyme cells need for energy metabolism and DNA repair. Niagen is the branded, patented form of NMN sold by ChromaDex, marketed as a dietary supplement ingredient ^[2]. No NMN product, branded or generic, has FDA approval as a drug for any condition in the United States. FDA's own position, laid out through the lens of the Federal Food, Drug, and Cosmetic Act's exclusionary clause, is that an ingredient first authorized for investigation as a new drug can't later be marketed as a dietary supplement, and NMN's status under that clause has been contested in ongoing litigation ^[3]. So you're comparing an approved drug being used off-label for nootropic and longevity claims, against a supplement ingredient whose own legal status as a supplement is unsettled. That's the core asymmetry to keep in mind through everything below.

How do methylene blue and NMN actually work in the body?

Methylene blue's approved mechanism is as an electron cycler and alternative electron acceptor in red blood cells, converting methemoglobin (iron in the Fe3+ state, can't bind oxygen) back to normal hemoglobin (Fe2+ state) ^[1]. Separately, in mitochondria, methylene blue can accept electrons from NADH and donate them to cytochrome c, essentially acting as an alternative electron carrier that bypasses complex I and III in some cell and animal models. This is the basis of the mitochondrial and nootropic buzz, but it comes almost entirely from in vitro and rodent studies, not human trials ^[4]. NMN's proposed mechanism is different: it's converted in cells to NAD+, a molecule required for hundreds of metabolic reactions including those run by sirtuins and PARP enzymes tied to DNA repair and cellular aging pathways. NAD+ levels do decline with age in various tissues, which is the rationale for supplementing precursors like NMN or NR (nicotinamide riboside). Human trials of NMN are small and short. A 2021 randomized controlled trial in postmenopausal women with prediabetes found 250 mg/day of NMN for 10 weeks improved insulin sensitivity in skeletal muscle, but did not significantly change body composition or other measures, and the study had only 25 participants ^[5]. That's the kind of evidence base we're working with: real signal, small numbers, short duration. Neither mechanism has been shown in a large, controlled human trial to produce clinically meaningful gains in energy, focus, or lifespan. Anyone telling you otherwise is overselling preclinical data.

What does the FDA actually approve each of these for?

Methylene blue injection (brand name Provayblue and generics) is FDA-approved specifically for acquired methemoglobinemia, at a labeled dose of 1 to 2 mg/kg given intravenously over several minutes ^[1]. That's it. The label carries no indication for cognitive enhancement, mitochondrial support, mood, or anti-aging use. Everything outside methemoglobinemia treatment (and a couple of other niche approved/studied uses) is off-label, meaning a prescriber can legally use clinical judgment to prescribe it that way, but the drug wasn't tested and approved by FDA for that purpose. NMN has zero FDA drug approvals. It exists in a gray zone: ChromaDex has marketed Niagen as a supplement ingredient for years ^[2]. Then FDA took the position that NMN had been authorized for investigation as a new drug before it was marketed as a supplement, which under the Federal Food, Drug, and Cosmetic Act's preclusion clause (21 U.S.C. § 321(ff)(3)(B)) would make it excluded from the dietary supplement definition ^[3]. Industry groups have pushed back and litigation over this is ongoing, so retail availability of NMN products hasn't stopped, but the legal footing is shakier than most marketing suggests.

Is one safer than the other?

They carry different risks, and neither is risk-free. Methylene blue's most serious documented risk is serotonin syndrome. It is a reversible, nonselective MAOI, and the FDA label carries a boxed warning against combining it with serotonergic drugs, including SSRIs, SNRIs, and other serotonin-affecting medications, because of case reports of serious and fatal reactions ^[1]. G6PD deficiency is a real, separate contraindication: in people with this enzyme deficiency, methylene blue can trigger hemolytic anemia instead of helping, because the drug's mechanism depends on an enzyme pathway (NADPH-dependent) that G6PD-deficient red cells can't run properly ^[1]. There's also a hard, safety-critical purity issue that has nothing to do with the drug's pharmacology: pharmaceutical-grade USP methylene blue is manufactured and tested to strict purity standards, while aquarium-grade or industrial-grade methylene blue sold for fish tanks or lab dye use can contain heavy metals and other contaminants not meant for human ingestion or injection. These are not interchangeable products, regardless of what a seller implies. NMN's safety data is thinner, mostly because it hasn't been studied as long or as widely in humans. Small trials, including the 25-person study cited above, reported no serious adverse events at doses up to 250 mg/day over 10 weeks ^[5], and other short trials have tested up to 900 mg/day for 12 weeks without major safety signals, but there's no long-term human safety data at scale, and manufacturing quality control varies a lot across supplement brands since NMN isn't held to drug-manufacturing standards. If you're buying NMN, you're trusting the supplement industry's quality control, which is considerably looser than pharmaceutical manufacturing oversight. Bottom line: methylene blue has clearer, well-documented risks (serotonin syndrome, G6PD hemolysis) precisely because it's been studied as a drug for over a century. NMN's risk profile is less charted, which isn't the same as being safer, it just means fewer people have looked hard enough to find problems.

Can you take methylene blue and NMN together?

There's no known direct pharmacological interaction between methylene blue and NMN reported in the literature, and they work through unrelated mechanisms (MAOI/electron transport vs NAD+ precursor). That said, the absence of a reported interaction isn't the same as proof of safety in combination, because nobody has run a formal drug interaction study on this specific pairing. The bigger practical issue is what else is in your regimen. If you're taking an SSRI, SNRI, tricyclic antidepressant, MAOI, triptan, tramadol, or St. John's Wort alongside methylene blue, the serotonin syndrome risk from methylene blue's MAOI activity is the dominant safety concern, not anything related to NMN ^[1]. Anyone combining these should talk to a prescriber first, ideally one who can review the full medication list, more than guess based on forum posts. For dosing specifics if methylene blue is already part of your plan, see Methylene Blue Bio dosage and Methylene Blue Bio half life for how long the drug and its interaction risk window actually last.

How do the claimed benefits for focus, energy, and longevity compare?

Does methylene blue really work as a nootropic, and how does that compare to NMN's cognitive claims?

The nootropic case for methylene blue rests mostly on animal studies showing improved memory retention in rodents at low doses, plus its known effect on cellular electron transport. Human data is sparse: a handful of small studies and case reports, some decades old, have looked at low-dose methylene blue for memory or mood, but nothing resembling a large modern randomized trial with cognitive endpoints in healthy adults ^[4]. It's an interesting hypothesis, not an established use. NMN's cognitive claims are, if anything, even thinner in humans. Most human NMN trials to date measure metabolic markers like insulin sensitivity, NAD+ blood levels, or physical performance measures, not standardized cognitive test batteries ^[5]. Any 'sharper focus' claim for NMN is currently extrapolation from the NAD+-and-aging story, not a demonstrated effect in a controlled human cognition study. If you're choosing between the two purely on nootropic grounds, you should know that both are riding on preclinical promise more than confirmed human outcomes. Treat marketing copy for either one that implies proven cognitive enhancement with real skepticism.

What's the deal with 'pharmaceutical grade' methylene blue versus what's sold online?

This distinction is not a marketing gimmick, it's a genuine safety line. USP (United States Pharmacopeia) grade methylene blue is manufactured to pharmaceutical purity standards, with controlled limits on heavy metals, residual solvents, and contaminants, and it's what's used in FDA-approved injectable products ^[1]. Aquarium-grade and industrial/laboratory-grade methylene blue are made for fish tank treatment or as a lab stain, not for human consumption, and they are not held to the same purity or contaminant testing. People sourcing methylene blue online for off-label nootropic or wellness use sometimes end up buying non-pharmaceutical grade product because it's cheaper and easier to find, without realizing the difference. That's a real risk, not a technicality: unknown contaminant levels in a compound you're ingesting or injecting is not something to gamble on. If you're going to use methylene blue outside its approved indication, the source and grade matter as much as the dose. A provider-reviewed route that sources pharmaceutical-grade material and dispenses through a licensed pharmacy (Methylene Blue Bio works with a fulfilling pharmacy partner rather than compounding anything itself) is a meaningfully different risk category than a bottle labeled for fish tanks. Check Methylene Blue Bio storage and shelf life and does Methylene Blue Bio need to be refrigerated for how proper handling affects a pharmaceutical-grade product's stability. NMN doesn't have an equivalent 'aquarium grade' danger, but supplement manufacturing quality still varies enormously since it isn't subject to drug GMP standards, so third-party testing (USP verified, NSF Certified for Sport, or similar) is the closest analogous safeguard for NMN buyers.

What are the real contraindications and warning signs to know before starting either one?

For methylene blue: G6PD deficiency is an absolute contraindication in most clinical guidance, because the drug can cause hemolytic anemia in these patients instead of correcting methemoglobinemia ^[1]. Serotonin syndrome is the other major warning: symptoms include agitation, high fever, rapid heart rate, muscle rigidity, and in severe cases, seizures or death, and it can occur when methylene blue is combined with SSRIs, SNRIs, or other serotonergic agents ^[1]. Pregnant patients and those with severe renal impairment also need specific medical guidance before use, per the drug label. For NMN: there's no established contraindication list of comparable weight, largely because rigorous long-term human safety trials haven't been run. That absence of red flags is a data gap, not a clean bill of health. People with cancer history should be cautious given some preclinical evidence that NAD+ boosting could theoretically support tumor metabolism, though this hasn't been confirmed as a clinical risk in humans; anyone with a cancer history should raise NMN use with their oncologist before starting. For either compound, unexplained symptoms after starting (confusion, high fever, unusual bruising, dark urine, jaundice) warrant stopping and getting medical attention, not waiting it out.

How are these two typically dosed, and does that affect risk?

Methylene blue's FDA-approved dose for methemoglobinemia is 1 to 2 mg/kg IV, and this differs sharply from the low oral 'microdoses' (often in the 0.5 to 2 mg/kg range, sometimes far lower, cited in off-label nootropic use) discussed in wellness contexts ^[1]. Off-label oral dosing protocols aren't standardized by any regulatory body, and reported ranges online vary widely and aren't validated by controlled trials. For anyone considering off-label use, review Methylene Blue Bio dosage and understand injection technique via Methylene Blue Bio injection sites if an injectable form is part of the plan, and talk to a prescriber rather than freelancing a dose from an online forum. NMN doses in published human trials have ranged from 250 mg/day up to 900 mg/day, generally over 8 to 12 weeks, without major reported adverse events at those doses ^[5]. But 'no adverse events in a 10 to 12 week trial of 25 to 100 people' is a low bar for confidence about long-term daily use over years, which is how most people marketing NMN products intend it to be taken. Higher doses of either compound don't automatically mean more benefit, and for methylene blue specifically, higher doses shift the mechanism from helpful (electron transport at low doses) toward the opposite effect at high doses, where the same MAOI activity that's therapeutic in one context becomes the mechanism behind serotonin toxicity in another.

What should someone actually do if they're considering either one?

If you're drawn to methylene blue for off-label energy or focus use, the responsible path is a conversation with a prescriber who can check your current medications for MAOI interactions, confirm you're not G6PD deficient, and, if it's appropriate, connect you to pharmaceutical-grade product through a licensed pharmacy rather than an unregulated online seller. Provider-reviewed routes exist for exactly this reason: they don't compound or manufacture anything, but they route you toward properly sourced, pharmacy-dispensed product with medical oversight built in, which matters given the USP-vs-aquarium-grade gap described above. If you're drawn to NMN, understand you're buying an ingredient with an unsettled legal status as a supplement in the US, no FDA-approved use, and a thin (though not alarming) human safety record. Look for third-party tested products, don't assume 'branded' means clinically validated, and don't expect measurable cognitive or longevity effects based on the current evidence. And know what you're not getting from either: neither methylene blue nor NMN is a proven longevity drug in humans. Anyone selling either one with confident anti-aging claims is ahead of the actual science. Check Methylene Blue Bio long term side effects before committing to ongoing use of methylene blue specifically, since most human data on it comes from short-term clinical use, not years of off-label daily dosing.

Frequently asked questions

Is methylene blue FDA-approved for energy or focus?

No. Methylene blue is FDA-approved only for treating methemoglobinemia ^[1]. Any use for energy, focus, mood, or anti-aging is off-label, meaning it's not part of the drug's approved indication, even though a doctor can legally prescribe it that way using clinical judgment.

Is NMN (Niagen) FDA-approved as a supplement?

NMN has no FDA drug approval, and its supplement status is contested. FDA has taken the position that NMN may not qualify as a legal dietary supplement ingredient because it was studied as a drug candidate first, a determination industry groups are challenging ^[3].

Can methylene blue cause serotonin syndrome?

Yes. Methylene blue is a monoamine oxidase inhibitor (MAOI), and the FDA drug label carries a specific warning against combining it with SSRIs, SNRIs, and other serotonergic drugs due to reports of serious, sometimes fatal serotonin syndrome ^[1].

Who should not take methylene blue?

People with G6PD deficiency generally should not take methylene blue, since it can trigger hemolytic anemia rather than correcting methemoglobinemia in this population ^[1]. People on serotonergic medications need prescriber guidance first because of the serotonin syndrome risk.

Is aquarium-grade methylene blue safe to take?

No. Aquarium and industrial-grade methylene blue aren't manufactured or tested to pharmaceutical (USP) purity standards and can contain contaminants not appropriate for human ingestion or injection. Only pharmaceutical-grade, prescription or pharmacy-dispensed methylene blue is appropriate for human use.

Does NMN actually raise NAD+ levels in humans?

Some small human trials show measurable increases in blood NAD+ related markers after NMN supplementation, alongside improvements in specific metabolic measures like insulin sensitivity in a 25-person trial of postmenopausal women ^[5]. Effects on broader health outcomes or lifespan in humans remain unproven.

Can I take methylene blue and NMN at the same time?

There's no documented direct interaction between the two, and they work through different mechanisms. The real risk to check is your other medications: if you take antidepressants or other serotonergic drugs, methylene blue's MAOI activity is the main concern, independent of NMN ^[1].

How is methylene blue dosed for methemoglobinemia versus off-label use?

The FDA-approved dose is 1 to 2 mg/kg given intravenously for methemoglobinemia ^[1]. Off-label oral 'microdosing' protocols cited in wellness contexts aren't standardized or validated by regulatory bodies, and doses vary widely across sources without controlled trial support.

What's the difference between NMN and NR for longevity claims?

Both NMN and NR (nicotinamide riboside) are NAD+ precursors studied for similar reasons, but they're chemically distinct molecules with separate small human trials. Neither has large-scale human data proving longevity benefits; both rest on biomarker changes in short trials, not lifespan outcomes.

Is methylene blue dangerous for people with G6PD deficiency?

Yes, this is a genuine, well-documented contraindication. In G6PD deficiency, methylene blue can't be properly recycled by red blood cells and instead promotes oxidative damage, potentially causing hemolytic anemia rather than treating methemoglobinemia ^[1]. Testing for G6PD status before use is standard clinical practice.

Does NMN have any known drug interactions?

Documented human drug interaction data for NMN is limited, reflecting how new and understudied it is compared to methylene blue. This isn't proof of safety with other drugs, just a gap in formal interaction studies; anyone on prescription medications should still check with a pharmacist or doctor before adding NMN.

Which is better supported by human evidence, methylene blue or NMN, for longevity?

Neither has strong human longevity evidence. Methylene blue's longevity case rests on rodent and cell studies; NMN's rests on rodent lifespan studies plus small human trials measuring biomarkers like insulin sensitivity over weeks, not years of outcome data ^[5]. Both are preclinical-to-early-human stage for this specific claim.

Sources

1. FDA, Methylene Blue Injection (Provayblue) prescribing information: Methylene blue's approved indication, MAOI mechanism, serotonin syndrome warning, G6PD contraindication, and 1-2 mg/kg dosing
2. ChromaDex Corporation, Form 10-K annual report (SEC EDGAR), Niagen/NMN product description: Niagen/NMN's marketing history as a branded dietary supplement ingredient sold by ChromaDex
3. 21 U.S.C. § 321(ff)(3)(B), Federal Food, Drug, and Cosmetic Act definitions: Legal basis (21 U.S.C. 321(ff)(3)(B)) for FDA's position that NMN may be excluded from the dietary supplement definition
4. Rojas JC, Bruchey AK, Gonzalez-Lima F, 'Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue', Progress in Neurobiology, 2012 (PMC4103016): Methylene blue's proposed mitochondrial electron transport mechanism is based largely on preclinical and rodent studies
5. Yoshino M, et al., 'Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women', Cell Metabolism, 2021 (PMID 33565984): 25-participant, 10-week RCT of 250 mg/day NMN improved muscle insulin sensitivity without significant body composition change